Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer: A Southwest Oncology Group study

G. K. Ellis, S. Green, S. Schulman, C. A. Coltman, H. E. Hynes, S. Rivkin, Robert B Livingston

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide. Twenty-five women were eligible and evaluable. Of these, complete response occurred in two patients (8%) and partial response in six patients (24%), for a total response rate of 32%. Toxicity was similar to that seen in previous Southwest Oncology Group (SWOG) trials in this patient population. Response rates in this study were inferior, with comparable median survivals to those of previous SWOG studies that are reviewed. Additional, more dose-intensive approaches incorporating newer approaches to the administration of cancer chemotherapeutic agents are planned.

Original languageEnglish (US)
Pages (from-to)934-939
Number of pages6
JournalCancer
Volume68
Issue number5
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Leucovorin
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Survival
Population
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer : A Southwest Oncology Group study. / Ellis, G. K.; Green, S.; Schulman, S.; Coltman, C. A.; Hynes, H. E.; Rivkin, S.; Livingston, Robert B.

In: Cancer, Vol. 68, No. 5, 1991, p. 934-939.

Research output: Contribution to journalArticle

@article{077ece887f7a48baa830278c957b485a,
title = "Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer: A Southwest Oncology Group study",
abstract = "Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide. Twenty-five women were eligible and evaluable. Of these, complete response occurred in two patients (8{\%}) and partial response in six patients (24{\%}), for a total response rate of 32{\%}. Toxicity was similar to that seen in previous Southwest Oncology Group (SWOG) trials in this patient population. Response rates in this study were inferior, with comparable median survivals to those of previous SWOG studies that are reviewed. Additional, more dose-intensive approaches incorporating newer approaches to the administration of cancer chemotherapeutic agents are planned.",
author = "Ellis, {G. K.} and S. Green and S. Schulman and Coltman, {C. A.} and Hynes, {H. E.} and S. Rivkin and Livingston, {Robert B}",
year = "1991",
doi = "10.1002/1097-0142(19910901)68:5<934::AID-CNCR2820680504>3.0.CO;2-N",
language = "English (US)",
volume = "68",
pages = "934--939",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer

T2 - A Southwest Oncology Group study

AU - Ellis, G. K.

AU - Green, S.

AU - Schulman, S.

AU - Coltman, C. A.

AU - Hynes, H. E.

AU - Rivkin, S.

AU - Livingston, Robert B

PY - 1991

Y1 - 1991

N2 - Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide. Twenty-five women were eligible and evaluable. Of these, complete response occurred in two patients (8%) and partial response in six patients (24%), for a total response rate of 32%. Toxicity was similar to that seen in previous Southwest Oncology Group (SWOG) trials in this patient population. Response rates in this study were inferior, with comparable median survivals to those of previous SWOG studies that are reviewed. Additional, more dose-intensive approaches incorporating newer approaches to the administration of cancer chemotherapeutic agents are planned.

AB - Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide. Twenty-five women were eligible and evaluable. Of these, complete response occurred in two patients (8%) and partial response in six patients (24%), for a total response rate of 32%. Toxicity was similar to that seen in previous Southwest Oncology Group (SWOG) trials in this patient population. Response rates in this study were inferior, with comparable median survivals to those of previous SWOG studies that are reviewed. Additional, more dose-intensive approaches incorporating newer approaches to the administration of cancer chemotherapeutic agents are planned.

UR - http://www.scopus.com/inward/record.url?scp=0026066708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026066708&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19910901)68:5<934::AID-CNCR2820680504>3.0.CO;2-N

DO - 10.1002/1097-0142(19910901)68:5<934::AID-CNCR2820680504>3.0.CO;2-N

M3 - Article

C2 - 1913489

AN - SCOPUS:0026066708

VL - 68

SP - 934

EP - 939

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -